课题基金 / 基金详情

PPG: SARS-CoV-host cell interactions and vaccine development

PPG: SARS-CoV-host cell interactions and vaccine development
PPG:SARS-CoV-宿主细胞相互作用和疫苗开发
批准号:
8021280
负责人:
Stanley Perlman
金额:
$159.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-01 至 2016-06-30
关键词:

项目摘要

项目成果

Stanley Perlman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: The Severe Acute Respiratory Syndrome, caused by a novel coronavlrus (SARS-CoV), resulted in substantial morbidity and mortality in 2002-2003. With the lack of recurrence of SARS, research efforts to understand pathogenesis and develop an effective vaccine have largely halted. However, coronaviruses similar to SARS-CoV have been identified in bats and other animal populations in China, making recurrence of SARS a possibility. Thus, we believe that efforts need to continue to understand pathogenesis and to develop vaccines and anti-viral therapies. In this PPG, several investigators with extensive experience in the pathogenesis, molecular biology and immunology of coronavirus infections will work together to better understand the interaction of SARS-CoV with the host respiratory tract and to develop novel approaches to preventing and treating SARS-CoV infections. These objectives will be investigated in the following projects. Project 1 will investigate severe disease in young BALB/c and aged BALB/c and C57BL/6 mice infected with mouse-adapted SARS-CoV and in SARS-CoV-infected mice that are transgenic for the human cellular receptor (angiotensin converting enzyme 2, hACE2). Project 2 will focus on the role of ACE2 signaling in pathogenesis. This project will also investigate the role of ACE2 by comparing cells and mice infected with SARS-CoV and HCoV-NL63, a common cold virus that also uses ACE2 to enter cells but does not cause severe disease. Project 3 will investigate the mechanism of action of two novel anti-virus therapies (rhesus theta defensin and griffithsin) and will investigate the role of ACE2 shedding in pathogenesis. Project 4 will develop and evaluate live attenuated SARS-CoV vaccines, based on the observation that virus deleted in the small envelope protein is viable, immunogenic and safe. All of the projects will use the Virology/Animal Models Core, which will engineer and propagate recombinant SARSCoV and will also analyze infected mice. Using the Core for these purposes will ensure reproducibility and ensure most effective use of our resources. These projects are all interrelated, will provide new information about SAR-CoV pathogenesis and will take advantage of the unique skills and expertise of the project directors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of eicosanoids in pathogenic human CoV infections
  • 批准号:
    9764251
  • 项目类别:
  • 资助金额:
    $54.52万
  • 财政年份:
    2016
  • 负责人:
    Stanley Perlman
  • 依托单位:
Role of eicosanoids in pathogenic human CoV infections
  • 批准号:
    9542722
  • 项目类别:
  • 资助金额:
    $54.52万
  • 财政年份:
    2016
  • 负责人:
    Stanley Perlman
  • 依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
  • 批准号:
    8847630
  • 项目类别:
  • 资助金额:
    $37.75万
  • 财政年份:
    2011
  • 负责人:
    Stanley Perlman
  • 依托单位:
Animal Core
  • 批准号:
    8055144
  • 项目类别:
  • 资助金额:
    $22.62万
  • 财政年份:
    2011
  • 负责人:
    Stanley Perlman
  • 依托单位:
国内基金
海外基金
SUMO化介导泛素化修饰类型调控N蛋白水平及SARS-CoV-2复制的机制研究
  • 批准号:
    JCZRQN202500077
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
SARS-CoV-2 VLP调控肿瘤微环境影响三阴性乳腺癌发生发展的机制 研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
  • 依托单位:
靶向SARS-CoV-2 S1蛋白中药多糖活性化合物的筛选及构效关系研究